157 related articles for article (PubMed ID: 37041215)
1. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Abou Dalle I; Labopin M; Kröger N; Schroeder T; Finke J; Stelljes M; Neubauer A; Blaise D; Yakoub-Agha I; Salmenniemi U; Forcade E; Itäla-Remes M; Dreger P; Bug G; Passweg J; Heuser M; Choi G; Brissot E; Giebel S; Nagler A; Ciceri F; Bazarbachi A; Mohty M
Bone Marrow Transplant; 2023 Jul; 58(7):784-790. PubMed ID: 37041215
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
Maffini E; Labopin M; Beelen DW; Kroeger N; Arat M; Wilson KMO; Bay JO; Ganser A; Martin H; Passweg J; Kottaridis PD; Yakoub-Agha I; Porras RP; Wagner EM; Esteve J; Lanza F; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Oct; 57(10):1556-1563. PubMed ID: 35835997
[TBL] [Abstract][Full Text] [Related]
4. Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler A; Labopin M; Dholaria B; Blaise D; Bondarenko S; Vydra J; Choi G; Rovira M; Reményi P; Meijer E; Bulabois CE; Diez-Martin JL; Yakoub-Agha I; Brissot E; Spyridonidis A; Sanz J; Patel A; Arat M; Bazarbachi A; Bug G; Savani BN; Giebel S; Ciceri F; Mohty M
Br J Haematol; 2023 Jun; 201(6):1169-1178. PubMed ID: 36949658
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH
Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275
[TBL] [Abstract][Full Text] [Related]
6. Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.
Jia X; Liao N; Yu S; Li H; Liu H; Zhang H; Xu J; Yao Y; He H; Yu G; Liu Q; Zhang Y; Shi P
Cancer Med; 2024 Feb; 13(4):e7074. PubMed ID: 38457215
[TBL] [Abstract][Full Text] [Related]
7. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
8. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
[TBL] [Abstract][Full Text] [Related]
10. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
Nagler A; Dholaria B; Labopin M; Socie G; Huynh A; Itälä-Remes M; Deconinck E; Yakoub-Agha I; Cahn JY; Bourhis JH; Labussière-Wallet H; Chantepie S; Esteve J; Savani B; Mohty M
Leukemia; 2020 Apr; 34(4):1144-1153. PubMed ID: 31728052
[TBL] [Abstract][Full Text] [Related]
11. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
[TBL] [Abstract][Full Text] [Related]
12. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
13. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
14. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Swoboda R; Kulagin A; Labussière-Wallet H; Rovira M; Blaise D; Vydra J; Yakoub-Agha I; Choi G; Reményi P; Koc Y; Sanz J; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):552-557. PubMed ID: 36823454
[TBL] [Abstract][Full Text] [Related]
16. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
[TBL] [Abstract][Full Text] [Related]
18. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
19. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Meur GL; Plesa A; Larcher MV; Fossard G; Barraco F; Loron S; Balsat M; Ducastelle-Leprêtre S; Gilis L; Thomas X; Ghesquières H; Tigaud I; Hayette S; Huet S; Sujobert P; Renault M; Thérèse RM; Michallet M; Labussière-Wallet H; Heiblig M
Transplant Cell Ther; 2023 Jan; 29(1):38.e1-38.e9. PubMed ID: 36108977
[TBL] [Abstract][Full Text] [Related]
20. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
